{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:57Z","timestamp":1793041977449,"version":"4.5.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11060-024-04876-z","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T23:25:45Z","timestamp":1731540345000},"page":"495-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws"],"prefix":"10.1007","volume":"171","author":[{"given":"Mohammadmahdi","family":"Sabahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Fathi Jouzdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohre","family":"Sadeghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Dabbagh Ohadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Salehipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Maniakhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badih","family":"Adada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Borghei-Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"4876_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nan.12432","volume":"44","author":"P Wesseling","year":"2018","unstructured":"Wesseling P, Capper D (2018) WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 44:139\u2013150","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4876_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/cmi.2017.159","volume":"15","author":"M Yao","year":"2018","unstructured":"Yao M, Li S, Wu X, Diao S, Zhang G, He H, Bian L, Lu Y (2018) Cellular origin of glioblastoma and its implication in precision therapy. Cell Mol Immunol 15:737","journal-title":"Cell Mol Immunol"},{"key":"4876_CR3","doi-asserted-by":"publisher","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","volume":"1","author":"M Weller","year":"2015","unstructured":"Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R (2015) Glioma. Nat Rev Dis Primers 1:15017","journal-title":"Nat Rev Dis Primers"},{"key":"4876_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D (2014) Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722","journal-title":"N Engl J Med"},{"key":"4876_CR5","doi-asserted-by":"publisher","first-page":"109559","DOI":"10.1016\/j.mehy.2020.109559","volume":"137","author":"M Sabahi","year":"2020","unstructured":"Sabahi M, Jabbari P, Haghighi MA, Soltani S, Soudi S, Rahmani F, Rezaei N (2020) Proposing a tandem AND gate CAR T cell targeting glioblastoma multiforme. Med Hypotheses 137:109559","journal-title":"Med Hypotheses"},{"key":"4876_CR6","doi-asserted-by":"publisher","first-page":"42997","DOI":"10.18632\/oncotarget.17792","volume":"8","author":"A Sattiraju","year":"2017","unstructured":"Sattiraju A, Sai KKS, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A (2017) IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget 8:42997","journal-title":"Oncotarget"},{"key":"4876_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1586\/14760584.5.6.793","volume":"5","author":"J Skog","year":"2006","unstructured":"Skog J (2006) Glioma-specific antigens for immune tumor therapy. Expert Rev Vaccines 5:793\u2013802","journal-title":"Expert Rev Vaccines"},{"key":"4876_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/labinvest.3700233","volume":"85","author":"D Zagzag","year":"2005","unstructured":"Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW (2005) Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 85:328\u2013341","journal-title":"Lab Invest"},{"key":"4876_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16:566","journal-title":"Nat Rev Cancer"},{"key":"4876_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2016.06.004","volume":"41","author":"M Sadelain","year":"2016","unstructured":"Sadelain M (2016) Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol 41:68\u201376","journal-title":"Curr Opin Immunol"},{"key":"4876_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.02.004","author":"F Locatelli","year":"2014","unstructured":"Locatelli F, Moretta F, Brescia L, Merli P (2014) Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol. https:\/\/doi.org\/10.1016\/j.smim.2014.02.004","journal-title":"Semin Immunol"},{"key":"4876_CR12","first-page":"764","volume":"117","author":"L Moretta","year":"2011","unstructured":"Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A (2011) Killer Ig\u2013like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood J Am Soc Hematol 117:764\u2013771","journal-title":"Blood J Am Soc Hematol"},{"key":"4876_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/bmt.2009.304","volume":"45","author":"SR Yoon","year":"2010","unstructured":"Yoon SR, Lee Y, Yang S, Ahn K, Lee J-H, Lee J-H, Kim D, Kang Y, Jeon M, Seol M (2010) Generation of donor natural killer cells from CD34\u2009+\u2009progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 45:1038\u20131046","journal-title":"Bone Marrow Transplant"},{"key":"4876_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui C-H, Leung W (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:955","journal-title":"J Clin Oncol"},{"key":"4876_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282\u20131295","journal-title":"Cancer Discov"},{"key":"4876_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528","journal-title":"Lancet"},{"key":"4876_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","volume":"132","author":"KS Campbell","year":"2013","unstructured":"Campbell KS, Hasegawa J (2013) Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132:536\u2013544. https:\/\/doi.org\/10.1016\/j.jaci.2013.07.006","journal-title":"J Allergy Clin Immunol"},{"key":"4876_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","volume":"31","author":"K-J Malmberg","year":"2017","unstructured":"Malmberg K-J, Carlsten M, Bj\u00f6rklund A, Sohlberg E, Bryceson YT, Ljunggren H-G (2017) Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol 31:20\u201329. https:\/\/doi.org\/10.1016\/j.smim.2017.08.002","journal-title":"Semin Immunol"},{"key":"4876_CR19","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17:1025\u20131036. https:\/\/doi.org\/10.1038\/ni.3518","journal-title":"Nat Immunol"},{"key":"4876_CR20","first-page":"127","volume-title":"Advances in cancer research","author":"J Wu","year":"2003","unstructured":"Wu J, Lanier LL (2003) Natural killer cells and cancer. In: Vande Woude GF, Klein G (eds) Advances in cancer research. Academic Press, NY, pp 127\u2013156"},{"key":"4876_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0074-7696(06)50006-3","volume":"250","author":"MA Santana","year":"2006","unstructured":"Santana MA, Esquivel-Guadarrama F (2006) Cell biology of T cell activation and differentiation. Int Rev Cytol 250:217\u2013274","journal-title":"Int Rev Cytol"},{"key":"4876_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","volume":"61","author":"S Agnihotri","year":"2013","unstructured":"Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, Zadeh G (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp 61:25\u201341","journal-title":"Arch Immunol Ther Exp"},{"key":"4876_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.trsl.2017.07.003","volume":"187","author":"A Rodriguez","year":"2017","unstructured":"Rodriguez A, Brown C, Badie B (2017) Chimeric antigen receptor T-cell therapy for glioblastoma. Translational Res 187:93\u2013102","journal-title":"Translational Res"},{"key":"4876_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fnins.2021.662064","volume":"15","author":"L Maggs","year":"2021","unstructured":"Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S (2021) CAR T cell-based immunotherapy for the treatment of glioblastoma. Front NeuroSci 15:535","journal-title":"Front NeuroSci"},{"key":"4876_CR25","doi-asserted-by":"publisher","first-page":"578146","DOI":"10.1016\/j.jneuroim.2023.578146","volume":"381","author":"M Sabahi","year":"2023","unstructured":"Sabahi M, Salehipour A, Bazl MSY, Rezaei N, Mansouri A, Borghei-Razavi H (2023) Local immunotherapy of glioblastoma: a comprehensive review of the concept. J Neuroimmunol 381:578146. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578146","journal-title":"J Neuroimmunol"},{"key":"4876_CR26","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD (2019) Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Translational Immunol 8:e1049. https:\/\/doi.org\/10.1002\/cti2.1049","journal-title":"Clin Translational Immunol"},{"key":"4876_CR27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA (2016) CD28 Costimulation: from mechanism to Therapy. Immunity 44:973\u2013988. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.020","journal-title":"Immunity"},{"key":"4876_CR28","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun S-C (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Therapy 2:17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23","journal-title":"Signal Transduct Target Therapy"},{"key":"4876_CR29","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G (2018) In vivo fate and activity of second- versus third-generation CD19-Specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas. Mol Therapy: J Am Soc Gene Therapy 26:2727\u20132737. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.009","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"4876_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257:83\u201390. https:\/\/doi.org\/10.1111\/imr.12125","journal-title":"Immunol Rev"},{"key":"4876_CR31","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ (2017) Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7:10541. https:\/\/doi.org\/10.1038\/s41598-017-10940-8","journal-title":"Sci Rep"},{"key":"4876_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739\u2013748","journal-title":"Nat Med"},{"key":"4876_CR33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843\u2013851","journal-title":"Mol Ther"},{"key":"4876_CR34","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A (2015) Human epidermal growth factor receptor 2 (HER2)\u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33:1688","journal-title":"J Clin Oncol"},{"key":"4876_CR35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS (2016) Phase I trial of anti\u2010PSMA designer CAR\u2010T cells in prostate cancer: possible role for interacting interleukin 2\u2010T cell pharmacodynamics as a determinant of clinical response. Prostate 76:1257\u20131270","journal-title":"Prostate"},{"key":"4876_CR36","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264\u20131270","journal-title":"Nat Med"},{"key":"4876_CR37","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561\u20132569","journal-title":"N Engl J Med"},{"key":"4876_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Therapy-Oncolytics. https:\/\/doi.org\/10.1038\/mto.2016.11","journal-title":"Mol Therapy-Oncolytics"},{"key":"4876_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, Chen C, Cheng KK-y, Chen T, Chang L-J (2023) Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer 22:3","journal-title":"Mol Cancer"},{"key":"4876_CR40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603:934\u2013941","journal-title":"Nature"},{"key":"4876_CR41","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani K, Rouce R, Liu E, Shpall E (2017) Engineering natural killer cells for cancer immunotherapy. Mol Ther 25:1769\u20131781. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012","journal-title":"Mol Ther"},{"key":"4876_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp S, Mufti G, Poirot L (2020) \u2018Off-the-shelf\u2019allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/s41573-019-0051-2","journal-title":"Nat Rev Drug Discov"},{"key":"4876_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12896-020-00665-4","volume":"21","author":"E Kamali","year":"2021","unstructured":"Kamali E, Rahbarizadeh F, Hojati Z, Fr\u00f6din M (2021) CRISPR\/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells. BMC Biotechnol 21:9. https:\/\/doi.org\/10.1186\/s12896-020-00665-4","journal-title":"BMC Biotechnol"},{"key":"4876_CR44","doi-asserted-by":"publisher","first-page":"1401683","DOI":"10.3389\/fimmu.2024.1401683","volume":"15","author":"K Pavlovic","year":"2024","unstructured":"Pavlovic K, Carmona-Luque M, Corsi GI, Maldonado-P\u00e9rez N, Molina-Estevez FJ, Peralbo-Santaella E, Cortijo-Guti\u00e9rrez M, Justicia-Lirio P, Trist\u00e1n-Manzano M, Ronco-D\u00edaz V, Ballesteros-Ribelles A, Mill\u00e1n-L\u00f3pez A, Heredia-Vel\u00e1zquez P, Fuster-Garc\u00eda C, Cathomen T, Seemann SE, Gorodkin J, Martin F, Herrera C, Benabdellah K (2024) Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR\/Cas9 editing and safety evaluation of the transcriptome. Front Immunol 15:1401683. https:\/\/doi.org\/10.3389\/fimmu.2024.1401683","journal-title":"Front Immunol"},{"key":"4876_CR45","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, Brown AE, Triggiano MA, Hux JA, Pham CD, Bartsevich VV, Turner CA, Lape J, Kirkland S, Beard CW, Smith J, Hirsch ML, Nicholson MG, Jantz D, McCreedy B (2017) Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther 25:949\u2013961. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.005","journal-title":"Mol Ther"},{"key":"4876_CR46","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.omto.2023.08.009","volume":"30","author":"W Zhou","year":"2023","unstructured":"Zhou W, Miao J, Cheng Z, Wang Z, Wang J, Guo H, Wang P, Lu S, Si L, Zhang Z, Dunmall LC, Liu Y, Lemoine NR, Wang Y (2023) Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL. Mol Ther Oncolytics 30:216\u2013226. https:\/\/doi.org\/10.1016\/j.omto.2023.08.009","journal-title":"Mol Ther Oncolytics"},{"key":"4876_CR47","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH (2013) The somatic genomic landscape of glioblastoma. Cell 155:462\u2013477","journal-title":"Cell"},{"key":"4876_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/01.COC.0000020922.66984.E7","volume":"26","author":"V Koka","year":"2003","unstructured":"Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M, Levitt R (2003) Role of Her-2\/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol 26:332\u2013335","journal-title":"Am J Clin Oncol"},{"key":"4876_CR49","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1158\/0008-5472.CAN-07-1493","volume":"67","author":"JS Jarboe","year":"2007","unstructured":"Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK (2007) Expression of interleukin-13 receptor \u03b12 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67:7983\u20137986","journal-title":"Cancer Res"},{"key":"4876_CR50","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396\u20131401","journal-title":"Science"},{"key":"4876_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98\u2013110","journal-title":"Cancer Cell"},{"key":"4876_CR52","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM (2019) An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178:835\u2013849 e821","journal-title":"Cell"},{"key":"4876_CR53","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK (2016) Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Investig 126:3036\u20133052","journal-title":"J Clin Investig"},{"key":"4876_CR54","first-page":"506","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu M-F, Orange JS, Sumazin P, Man T-K (2018) Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neurooncology 20:506\u2013518","journal-title":"Neurooncology"},{"key":"4876_CR55","doi-asserted-by":"publisher","first-page":"eaaw2672","DOI":"10.1126\/scitranslmed.aaw2672","volume":"12","author":"D Wang","year":"2020","unstructured":"Wang D, Starr R, Chang W-C, Aguilar B, Alizadeh D, Wright SL, Yang X, Brito A, Sarkissian A, Ostberg JR (2020) Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med 12:eaaw2672","journal-title":"Sci Transl Med"},{"key":"4876_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99048","author":"D Wang","year":"2018","unstructured":"Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, Ostberg JR, Forman SJ, Brown CE (2018) Glioblastoma-targeted CD4 + CAR T cells mediate superior antitumor activity. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.99048","journal-title":"JCI Insight"},{"key":"4876_CR57","first-page":"1429","volume":"20","author":"SJ Bagley","year":"2018","unstructured":"Bagley SJ, Desai AS, Linette GP, June CH, O\u2019Rourke DM (2018) CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neurooncology 20:1429\u20131438","journal-title":"Neurooncology"},{"key":"4876_CR58","doi-asserted-by":"publisher","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya D, Dutoit V, Migliorini D (2021) Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol 12:640082","journal-title":"Front Immunol"},{"key":"4876_CR59","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128","journal-title":"Front Immunol"},{"key":"4876_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","volume":"19","author":"CE Brown","year":"2019","unstructured":"Brown CE, Mackall CL (2019) CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol 19:73\u201374","journal-title":"Nat Rev Immunol"},{"key":"4876_CR61","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W-C, Naranjo A, Starr R, Wagner J, Wright C (2015) Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8\u2009+\u2009T cells in patients with recurrent glioblastoma. Clin Cancer Res 21:4062\u20134072","journal-title":"Clin Cancer Res"},{"key":"4876_CR62","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu M-F, Liu H, Dotti G, Balyasnikova IV, Gottschalk S (2017) Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res 5:571\u2013581","journal-title":"Cancer Immunol Res"},{"key":"4876_CR63","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJ, Martinez-Lage M, Brem S, Maloney E, Shen A (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9:eaaa0984","journal-title":"Sci Transl Med"},{"key":"4876_CR64","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"28","author":"JH Sampson","year":"2010","unstructured":"Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722","journal-title":"J Clin Oncol"},{"key":"4876_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJ, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568:112\u2013116","journal-title":"Nature"},{"key":"4876_CR66","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","volume":"15","author":"VA Arrieta","year":"2024","unstructured":"Arrieta VA, Gould A, Kim KS, Habashy KJ, Dmello C, V\u00e1zquez-Cervantes GI, Palac\u00edn-Aliana I, McManus G, Amidei C, Gomez C, Dhiantravan S, Chen L, Zhang DY, Saganty R, Cholak ME, Pandey S, McCord M, McCortney K, Castro B, Ward R, Muzzio M, Bouchoux G, Desseaux C, Canney M, Carpentier A, Zhang B, Miska JM, Lesniak MS, Horbinski CM, Lukas RV, Stupp R, Lee-Chang C, Sonabend AM (2024) Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat Commun 15:4698. https:\/\/doi.org\/10.1038\/s41467-024-48326-w","journal-title":"Nat Commun"},{"key":"4876_CR67","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T (2022) Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia 36:1943\u20131946. https:\/\/doi.org\/10.1038\/s41375-022-01585-2","journal-title":"Leukemia"},{"key":"4876_CR68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","volume":"8","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C, Wang D, Shi Z, Yan X, Li X, Jiang T, Zhang W (2023) Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Signal Transduct Target Therapy 8:457. https:\/\/doi.org\/10.1038\/s41392-023-01708-w","journal-title":"Signal Transduct Target Therapy"},{"key":"4876_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cells13131075","author":"D Akhavan","year":"2024","unstructured":"Akhavan D, Subham S, Jeppson JD, Aguilar B, Wong RA, Hibbard JC, Hui S, Wong JYC, Forman SJ, Alizadeh D, Brown CE (2024) Evaluation of the immunomodulatory effects of radiation for chimeric antigen receptor T cell therapy in glioblastoma multiforme. Cells. https:\/\/doi.org\/10.3390\/cells13131075","journal-title":"Cells"},{"key":"4876_CR70","doi-asserted-by":"publisher","first-page":"1299044","DOI":"10.3389\/fimmu.2024.1299044","volume":"15","author":"LB Nabors","year":"2024","unstructured":"Nabors LB, Lamb LS, Goswami T, Rochlin K, Youngblood SL (2024) Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified \u03b3\u03b4 t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions. Front Immunol 15:1299044. https:\/\/doi.org\/10.3389\/fimmu.2024.1299044","journal-title":"Front Immunol"},{"key":"4876_CR71","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3389\/fimmu.2020.01402","volume":"11","author":"S DeCordova","year":"2020","unstructured":"DeCordova S, Shastri A, Tsolaki AG, Yasmin H, Klein L, Singh SK, Kishore U (2020) Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. Front Immunol 11:1402. https:\/\/doi.org\/10.3389\/fimmu.2020.01402","journal-title":"Front Immunol"},{"key":"4876_CR72","doi-asserted-by":"publisher","first-page":"1003651","DOI":"10.3389\/fimmu.2022.1003651","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhao L, Zhang H, Zhang Y, Ju H, Wang X, Ren H, Zhu X, Dong Y (2022) The immunosuppressive microenvironment and immunotherapy in human glioblastoma. Front Immunol 13:1003651","journal-title":"Front Immunol"},{"key":"4876_CR73","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","volume":"12","author":"LJ Hansen","year":"2022","unstructured":"Hansen LJ, Yang R, Roso K, Wang W, Chen L, Yang Q, Pirozzi CJ, He Y (2022) MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization. Sci Rep 12:4183","journal-title":"Sci Rep"},{"key":"4876_CR74","doi-asserted-by":"publisher","first-page":"819363","DOI":"10.3389\/fncel.2022.819363","volume":"16","author":"Z Qi","year":"2022","unstructured":"Qi Z, Long X, Liu J, Cheng P (2022) Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. Front Cell Neurosci 16:819363","journal-title":"Front Cell Neurosci"},{"key":"4876_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177141","author":"R Hatae","year":"2024","unstructured":"Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H (2024) Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.177141","journal-title":"JCI Insight"},{"key":"4876_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005719","author":"V Finisguerra","year":"2023","unstructured":"Finisguerra V, Dvorakova T, Formenti M, Van Meerbeeck P, Mignion L, Gallez B, Van den Eynde BJ (2023) Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005719","journal-title":"J Immunother Cancer"},{"key":"4876_CR77","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.2337\/db13-0368","volume":"62","author":"DG Hardie","year":"2013","unstructured":"Hardie DG (2013) AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62:2164\u20132172. https:\/\/doi.org\/10.2337\/db13-0368","journal-title":"Diabetes"},{"key":"4876_CR78","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi Y, Kotchetkov IS, Dobrin A, Hanina SA, Rajasekhar VK, Healey JH, Sadelain M (2024) GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther 32:2393\u20132405. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.006","journal-title":"Mol Ther"},{"key":"4876_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02060-8","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, Wang Y, Gao M, Hu X, Romero P, Carmona S, Sun J, Guo Y, Tang L (2024) IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-02060-8","journal-title":"Nat Biotechnol"},{"key":"4876_CR80","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41416-021-01515-6","volume":"125","author":"SS Widodo","year":"2021","unstructured":"Widodo SS, Dinevska M, Furst LM, Stylli SS, Mantamadiotis T (2021) IL-10 in glioma. Br J Cancer 125:1466\u20131476. https:\/\/doi.org\/10.1038\/s41416-021-01515-6","journal-title":"Br J Cancer"},{"key":"4876_CR81","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, Hicks KA, Zhang JV, Zhang L, Xie C, Wang J, Wang T, Xu J, Fraietta JA, Binder ZA, Lin Z, O\u2019Rourke DM (2024) Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther 32:3522\u20133538. https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.020","journal-title":"Mol Ther"},{"key":"4876_CR82","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","volume":"26","author":"AJ Hou","year":"2024","unstructured":"Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, Guemes M, Galic Z, Phyu S, Okada H, Grausam KB, Breunig JJ, Brown CE, Nathanson DA, Prins RM, Chen YY (2024) IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol 26:1850\u20131866. https:\/\/doi.org\/10.1093\/neuonc\/noae126","journal-title":"Neuro Oncol"},{"key":"4876_CR83","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA (2015) Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125:3905\u20133916. https:\/\/doi.org\/10.1182\/blood-2015-01-621474","journal-title":"Blood"},{"key":"4876_CR84","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1158\/1078-0432.Ccr-21-1392","volume":"27","author":"L Zhai","year":"2021","unstructured":"Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, Genet M, Kim M, Chen P, Mi X, Wu JD, Schipma MJ, Wray B, Griffiths J, Unwin RD, Clark SJ, Acharya R, Bao R, Horbinski C, Lukas RV, Schiltz GE, Wainwright DA (2021) Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clin Cancer Res 27:6514\u20136528. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1392","journal-title":"Clin Cancer Res"},{"key":"4876_CR85","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/2326-6066.Cir-21-1075","volume":"10","author":"AR S\u00e1nchez-Paulete","year":"2022","unstructured":"S\u00e1nchez-Paulete AR, Mateus-Tique J, Mollaoglu G, Nielsen SR, Marks A, Lakshmi A, Khan JA, Wilk CM, Pia L, Baccarini A, Merad M, Brown BD (2022) Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity. Cancer Immunol Res 10:1354\u20131369. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-1075","journal-title":"Cancer Immunol Res"},{"key":"4876_CR86","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L (2024) Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol 8:31. https:\/\/doi.org\/10.1038\/s41698-024-00522-z","journal-title":"NPJ Precis Oncol"},{"key":"4876_CR87","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11060-015-1849-3","volume":"123","author":"AP See","year":"2015","unstructured":"See AP, Parker JJ, Waziri A (2015) The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression. J Neurooncol 123:405\u2013412","journal-title":"J Neurooncol"},{"key":"4876_CR88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/B:NEON.0000040821.50347.c5","volume":"70","author":"MS Lesniak","year":"2004","unstructured":"Lesniak MS, Gabikian P, Tyler BM, Pardoll DM, Brem H (2004) Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 70:23\u201328","journal-title":"J Neurooncol"},{"key":"4876_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3171\/jns.2000.93.4.0634","volume":"93","author":"B Badie","year":"2000","unstructured":"Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK (2000) Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 93:634\u2013639","journal-title":"J Neurosurg"},{"key":"4876_CR90","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4049\/jimmunol.133.1.273","volume":"133","author":"S Arya","year":"1984","unstructured":"Arya S, Wong-Staal F, Gallo R (1984) Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA. J Immunol (Baltimore Md: 1950) 133:273\u2013276","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"4876_CR91","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB (2012) Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"4876_CR92","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS (2013) Safety and tumor responses with lambrolizumab (anti\u2013PD-1) in melanoma. N Engl J Med 369:134\u2013144","journal-title":"N Engl J Med"},{"key":"4876_CR93","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS (2015) Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science 348:124\u2013128","journal-title":"Science"},{"key":"4876_CR94","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4446","author":"H Abid","year":"2019","unstructured":"Abid H, Watthanasuntorn K, Shah O, Gnanajothy R (2019) Efficacy of pembrolizumab and nivolumab in crossing the blood brain barrier. Cureus. https:\/\/doi.org\/10.7759\/cureus.4446","journal-title":"Cureus"},{"key":"4876_CR95","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477\u2013486","journal-title":"Nat Med"},{"key":"4876_CR96","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, L\u00f3pez-Janeiro A, Porciuncula A, Idoate MA, Inog\u00e9s S, De Andrea C, de L\u00f3pez-Diaz CA, Tejada S (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:470\u2013476","journal-title":"Nat Med"},{"key":"4876_CR97","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A (2019) Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 25:462\u2013469","journal-title":"Nat Med"},{"key":"4876_CR98","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B (2018) Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scfv-based CAR T cells to treat murine and canine gliomas. Mol Therapy-Oncolytics 11:20\u201338","journal-title":"Mol Therapy-Oncolytics"},{"key":"4876_CR99","first-page":"1549","volume":"42","author":"L Shen","year":"2019","unstructured":"Shen L, Li H, Bin S, Li P, Chen J, Gu H, Yuan W (2019) The efficacy of third generation anti\u2013HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells. Oncol Rep 42:1549\u20131557","journal-title":"Oncol Rep"},{"key":"4876_CR100","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24:1459\u20131468","journal-title":"Nat Med"},{"key":"4876_CR101","doi-asserted-by":"publisher","first-page":"e1434464","DOI":"10.1080\/2162402X.2018.1434464","volume":"7","author":"CM Suryadevara","year":"2018","unstructured":"Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ (2018) Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology 7:e1434464","journal-title":"Oncoimmunology"},{"key":"4876_CR102","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma L, Dichwalkar T, Chang JY, Cossette B, Garafola D, Zhang AQ, Fichter M, Wang C, Liang S, Silva M (2019) Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365:162\u2013168","journal-title":"Science"},{"key":"4876_CR103","doi-asserted-by":"publisher","first-page":"e0199414","DOI":"10.1371\/journal.pone.0199414","volume":"13","author":"A Sahin","year":"2018","unstructured":"Sahin A, Sanchez C, Bullain S, Waterman P, Weissleder R, Carter BS (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS ONE 13:e0199414","journal-title":"PLoS ONE"},{"key":"4876_CR104","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/hum.2017.234","volume":"30","author":"B Hu","year":"2019","unstructured":"Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X (2019) Nucleofection with plasmid DNA for CRISPR\/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther 30:446\u2013458","journal-title":"Hum Gene Ther"},{"key":"4876_CR105","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 7:1238\u20131247","journal-title":"Cancer Discov"},{"key":"4876_CR106","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB (2019) CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 37:1049\u20131058","journal-title":"Nat Biotechnol"},{"key":"4876_CR107","doi-asserted-by":"publisher","first-page":"108734","DOI":"10.1016\/j.biopha.2019.108734","volume":"113","author":"M Chen","year":"2019","unstructured":"Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H (2019) Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL\/6 mice. Biomed Pharmacother 113:108734","journal-title":"Biomed Pharmacother"},{"key":"4876_CR108","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-18-0044","volume":"6","author":"H Jiang","year":"2018","unstructured":"Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z (2018) Selective targeting of glioblastoma with EGFRvIII\/EGFR bitargeted chimeric antigen receptor T cell. Cancer Immunol Res 6:1314\u20131326","journal-title":"Cancer Immunol Res"},{"key":"4876_CR109","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3389\/fonc.2020.01117","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Wu H, Chen G, Wei X, Wang C, Zhou S, Huang A, Zhang Z, Zhan C, Wu Y (2020) Arming anti-EGFRvIII CAR-T with TGF\u03b2 trap improves antitumor efficacy in glioma mouse models. Front Oncol 10:1117","journal-title":"Front Oncol"},{"key":"4876_CR110","doi-asserted-by":"publisher","first-page":"904133","DOI":"10.3389\/fimmu.2022.904133","volume":"13","author":"G Wang","year":"2022","unstructured":"Wang G, Wang W (2022) Advanced cell therapies for glioblastoma. Front Immunol 13:904133","journal-title":"Front Immunol"},{"key":"4876_CR111","doi-asserted-by":"publisher","first-page":"v234","DOI":"10.1093\/neuonc\/noad179.0897","volume":"25","author":"T Martins","year":"2023","unstructured":"Martins T, Tatari N, Kaymak D, Bartoszek EM, Hogan S, Buck A, Ritz M-F, Wieboldt R, McDaid M, Gerber A, Shekarian T, Hedad HMS, Schmassmann P, Weiss T, Laeubli H, Hutter G (2023) EXTH-44. ENHANCING GLIOBLASTOMA CLEARANCE: EMPOWERING ANTI-EGFRVIII CAR T CELLS WITH A PARACRINE SIRP\u0393-DERIVED CD47 BLOCKER. Neurooncology 25:v234\u2013v234. https:\/\/doi.org\/10.1093\/neuonc\/noad179.0897","journal-title":"Neurooncology"},{"key":"4876_CR112","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E (2019) Neoantigen vaccine generates intratumoral T cell responses in phase ib glioblastoma trial. Nature 565:234\u2013239","journal-title":"Nature"},{"key":"4876_CR113","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","author":"S Guedan","year":"2018","unstructured":"Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M (2018) Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.96976","journal-title":"JCI Insight"},{"key":"4876_CR114","doi-asserted-by":"publisher","first-page":"e20192203","DOI":"10.1084\/jem.20192203","volume":"218","author":"E Lanitis","year":"2020","unstructured":"Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, Romero P, Dangaj D, Coukos G, Irving M (2020) Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med 218:e20192203","journal-title":"J Exp Med"},{"key":"4876_CR115","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP (2016) GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 24:1135\u20131149","journal-title":"Mol Ther"},{"key":"4876_CR116","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/hum.2017.254","volume":"29","author":"U K\u00f6hl","year":"2018","unstructured":"K\u00f6hl U, Arsenieva S, Holzinger A, Abken H (2018) CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum Gene Ther 29:559\u2013568","journal-title":"Hum Gene Ther"},{"key":"4876_CR117","first-page":"1318","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, Aguilar B, Starr R, Weng L, Synold TW (2022) Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neurooncology 24:1318\u20131330","journal-title":"Neurooncology"},{"key":"4876_CR118","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L (2018) A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175:313\u2013326. https:\/\/doi.org\/10.1016\/j.cell.2018.09.035","journal-title":"Cell"},{"key":"4876_CR119","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.smim.2014.02.004","volume":"26","author":"F Locatelli","year":"2014","unstructured":"Locatelli F, Moretta F, Brescia L, Merli P (2014) Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol 26:173\u2013179. https:\/\/doi.org\/10.1016\/j.smim.2014.02.004","journal-title":"Semin Immunol"},{"key":"4876_CR120","first-page":"202","volume":"6","author":"AG Navarro","year":"2015","unstructured":"Navarro AG, Bj\u00f6rklund A, Chekenya M (2015) Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol 6:202","journal-title":"Front Immunol"},{"key":"4876_CR121","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"K Rezvani","year":"2015","unstructured":"Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578","journal-title":"Front Immunol"},{"key":"4876_CR122","doi-asserted-by":"publisher","first-page":"79187","DOI":"10.18632\/oncotarget.13007","volume":"7","author":"F Jin","year":"2016","unstructured":"Jin F, Lin H, Gao S, Hu Z, Zuo S, Sun L, Jin C, Li W, Yang Y (2016) The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia. Oncotarget 7:79187","journal-title":"Oncotarget"},{"key":"4876_CR123","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","volume":"97","author":"BE Swift","year":"2012","unstructured":"Swift BE, Williams BA, Kosaka Y, Wang X-H, Medin JA, Viswanathan S, Martinez-Lopez J, Keating A (2012) Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 97:1020","journal-title":"Haematologica"},{"key":"4876_CR124","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell aloreactivity in mismatched hematopoietic transplants. Science 295:2097\u20132100","journal-title":"Science"},{"key":"4876_CR125","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS (2010) NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115:4293\u20134301","journal-title":"Blood"},{"key":"4876_CR126","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051\u20133057. https:\/\/doi.org\/10.1182\/blood-2004-07-2974","journal-title":"Blood"},{"key":"4876_CR127","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher M, Rezvani K (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146\u2013153. https:\/\/doi.org\/10.1016\/j.coi.2018.03.013","journal-title":"Curr Opin Immunol"},{"key":"4876_CR128","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS (2017) Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol 8:533. https:\/\/doi.org\/10.3389\/fimmu.2017.00533","journal-title":"Front Immunol"},{"key":"4876_CR129","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fimmu.2017.00654","volume":"8","author":"O Oberschmidt","year":"2017","unstructured":"Oberschmidt O, Kloess S, Koehl U (2017) Redirected primary human chimeric antigen receptor natural killer cells as an off-the-shelf immunotherapy for improvement in cancer treatment. Front Immunol 8:654. https:\/\/doi.org\/10.3389\/fimmu.2017.00654","journal-title":"Front Immunol"},{"key":"4876_CR130","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4049\/jimmunol.1701155","volume":"200","author":"S Srivastava","year":"2018","unstructured":"Srivastava S, Riddell SR (2018) Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol 200:459\u2013468. https:\/\/doi.org\/10.4049\/jimmunol.1701155","journal-title":"J Immunol"},{"key":"4876_CR131","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu W, Wang G, Huang D, Sui M, Xu Y (2019) Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol 10:1205\u20131205. https:\/\/doi.org\/10.3389\/fimmu.2019.01205","journal-title":"Front Immunol"},{"key":"4876_CR132","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jcyt.2016.05.018","volume":"18","author":"RA Burga","year":"2016","unstructured":"Burga RA, Nguyen T, Zulovich J, Madonna S, Ylisastigui L, Fernandes R, Yvon E (2016) Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. Cytotherapy 18:1410\u20131421. https:\/\/doi.org\/10.1016\/j.jcyt.2016.05.018","journal-title":"Cytotherapy"},{"key":"4876_CR133","doi-asserted-by":"publisher","first-page":"1368290","DOI":"10.3389\/fimmu.2024.1368290","volume":"15","author":"EP van Hees","year":"2024","unstructured":"van Hees EP, Morton LT, Remst DFG, Wouters AK, Van den Eynde A, Falkenburg JHF, Heemskerk MHM (2024) Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence. Front Immunol 15:1368290. https:\/\/doi.org\/10.3389\/fimmu.2024.1368290","journal-title":"Front Immunol"},{"key":"4876_CR134","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","volume":"6","author":"M Carlsten","year":"2015","unstructured":"Carlsten M, Childs RW (2015) Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol 6:266","journal-title":"Front Immunol"},{"key":"4876_CR135","doi-asserted-by":"publisher","first-page":"e27196","DOI":"10.1016\/j.heliyon.2024.e27196","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian K, Zhang D, Hu P, He Z, Zhang Z, Wang Y (2024) CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon 10:e27196. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27196","journal-title":"Heliyon"},{"key":"4876_CR136","doi-asserted-by":"publisher","first-page":"e0142767","DOI":"10.1371\/journal.pone.0142767","volume":"10","author":"NS Sta Maria","year":"2015","unstructured":"Sta Maria NS, Barnes SR, Weist MR, Colcher D, Raubitschek AA, Jacobs RE (2015) Low dose focused Ultrasound induces enhanced tumor accumulation of natural killer cells. PLoS ONE 10:e0142767. https:\/\/doi.org\/10.1371\/journal.pone.0142767","journal-title":"PLoS ONE"},{"key":"4876_CR137","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nov318","volume":"18","author":"R Alkins","year":"2016","unstructured":"Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K (2016) Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro Oncol 18:974\u2013981. https:\/\/doi.org\/10.1093\/neuonc\/nov318","journal-title":"Neuro Oncol"},{"key":"4876_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.09.010","author":"M S\u00e6tersmoen","year":"2024","unstructured":"S\u00e6tersmoen M, Kotchetkov IS, Torralba-Raga L, Mansilla-Soto J, Sohlberg E, Krokeide SZ, Hammer Q, Sadelain M, Malmberg KJ (2024) Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor. Med. https:\/\/doi.org\/10.1016\/j.medj.2024.09.010","journal-title":"Med"},{"key":"4876_CR139","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/21645515.2015.1096458","volume":"12","author":"S Murray","year":"2016","unstructured":"Murray S, Lundqvist A (2016) Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: on being in the right place at the right time, with resilience. Hum Vaccines Immunotherapeutics 12:607\u2013611","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"4876_CR140","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16:7\u201319. https:\/\/doi.org\/10.1038\/nrc.2015.5","journal-title":"Nat Rev Cancer"},{"key":"4876_CR141","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcyt.2014.09.007","volume":"17","author":"H Klingemann","year":"2015","unstructured":"Klingemann H (2015) Challenges of cancer therapy with natural killer cells. Cytotherapy 17:245\u2013249. https:\/\/doi.org\/10.1016\/j.jcyt.2014.09.007","journal-title":"Cytotherapy"},{"key":"4876_CR142","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3171\/2016.9.JNS16943","volume":"128","author":"VS Madhugiri","year":"2018","unstructured":"Madhugiri VS, Teo MKC, Vavao J, Bell-Stephens T, Steinberg GK (2018) Brainstem arteriovenous malformations: lesion characteristics and treatment outcomes. J Neurophysiol 128:126\u2013136. https:\/\/doi.org\/10.3171\/2016.9.JNS16943","journal-title":"J Neurophysiol"},{"key":"4876_CR143","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1002\/cti2.1507","volume":"13","author":"A Pfefferle","year":"2024","unstructured":"Pfefferle A, Contet J, Wong K, Chen C, Verhoeyen E, Slichter CK, Schluns KS, Cursons J, Berry R, Nikolic I (2024) Optimisation of a primary human CAR-NK cell manufacturing pipeline. Clin Transl Immunol 13:e1507","journal-title":"Clin Transl Immunol"},{"key":"4876_CR144","first-page":"2058","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger MC, Forster M-T, Romanski A, Stra\u00dfheimer F, Macas J, Zeiner PS, Steidl E, Herkt S, Weber KJ, Schupp J (2023) Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neurooncology 25:2058\u20132071","journal-title":"Neurooncology"},{"key":"4876_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N, Kleeff J, Liao Q, Wu W (2023) Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer 22:1\u201327","journal-title":"Mol Cancer"},{"key":"4876_CR146","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","volume":"42","author":"D Eisenbarth","year":"2023","unstructured":"Eisenbarth D, Wang YA (2023) Glioblastoma heterogeneity at single cell resolution. Oncogene 42:2155\u20132165. https:\/\/doi.org\/10.1038\/s41388-023-02738-y","journal-title":"Oncogene"},{"key":"4876_CR147","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11899-021-00628-2","volume":"16","author":"M Schwerdtfeger","year":"2021","unstructured":"Schwerdtfeger M, Benmebarek M-R, Endres S, Subklewe M, Desiderio V, Kobold S (2021) Chimeric antigen receptor\u2013modified T cells and T cell\u2013engaging bispecific antibodies: different tools for the same job. Curr Hematol Malig Rep 16:218\u2013233","journal-title":"Curr Hematol Malig Rep"},{"key":"4876_CR148","doi-asserted-by":"publisher","first-page":"2203106","DOI":"10.1002\/advs.202203106","volume":"9","author":"D Wang","year":"2022","unstructured":"Wang D, Zhang M, Zhang Y, Qiu G, Chen J, Zhu X, Kong C, Lu X, Liang X, Duan L (2022) Intraparticle double-scattering\u2010decoded sonogenetics for augmenting immune checkpoint blockade and CAR\u2010T therapy. Adv Sci 9:2203106","journal-title":"Adv Sci"},{"key":"4876_CR149","first-page":"2308","volume":"136","author":"M Gang","year":"2020","unstructured":"Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M (2020) CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood J Am Soc Hematol 136:2308\u20132318","journal-title":"Blood J Am Soc Hematol"},{"key":"4876_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102619","author":"AL Portillo","year":"2021","unstructured":"Portillo AL, Hogg R, Poznanski SM, Rojas EA, Cashell NJ, Hammill JA, Chew MV, Shenouda MM, Ritchie TM, Cao QT (2021) Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. Iscience. https:\/\/doi.org\/10.1016\/j.isci.2021.102619","journal-title":"Iscience"},{"key":"4876_CR151","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002866","author":"M Bachiller","year":"2021","unstructured":"Bachiller M, Perez-Amill L, Battram AM, Carn\u00e9 SC, Najjar A, Verhoeyen E, Juan M, Urbano-Ispizua A, Martin-Antonio B (2021) NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002866","journal-title":"J Immunother Cancer"},{"key":"4876_CR152","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV (2024) Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med 390:1290\u20131298. https:\/\/doi.org\/10.1056\/NEJMoa2314390","journal-title":"N Engl J Med"},{"key":"4876_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02462-y","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Saleh MM, Rahman HS, Suksatan W, Al-Gazally ME, Abdelbasset WK, Thangavelu L, Yumashev AV, Hassanzadeh A, Yazdanifar M (2021) CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther 12:1\u201318","journal-title":"Stem Cell Res Ther"},{"key":"4876_CR154","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","volume":"78","author":"T Weiss","year":"2018","unstructured":"Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P (2018) NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res 78:1031\u20131043","journal-title":"Cancer Res"},{"key":"4876_CR155","doi-asserted-by":"publisher","first-page":"1298683","DOI":"10.3389\/fimmu.2023.1298683","volume":"14","author":"J He","year":"2023","unstructured":"He J, Yan Y, Zhang J, Wei Z, Li H, Xing L (2023) Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors. Front Immunol 14:1298683","journal-title":"Front Immunol"},{"key":"4876_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00998-9","volume":"13","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A, Cui H, Caligiuri MA, Yu J (2020) Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol 13:1\u201322","journal-title":"J Hematol Oncol"},{"key":"4876_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J (2020) CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975","journal-title":"EBioMedicine"},{"key":"4876_CR158","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers14174318","volume":"14","author":"Z Pang","year":"2022","unstructured":"Pang Z, Wang Z, Li F, Feng C, Mu X (2022) Current progress of CAR-NK therapy in cancer treatment. Cancers 14:4318","journal-title":"Cancers"},{"key":"4876_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RG, Wang J, Bos GM, Germeraad WT (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 14:1\u201335","journal-title":"J Hematol Oncol"},{"key":"4876_CR160","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","volume":"114","author":"A Biederst\u00e4dt","year":"2021","unstructured":"Biederst\u00e4dt A, Rezvani K (2021) Engineering the next generation of CAR-NK immunotherapies. Int J Hematol 114:554\u2013571","journal-title":"Int J Hematol"},{"key":"4876_CR161","doi-asserted-by":"publisher","first-page":"822298","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel KE, Fricke S, K\u00f6hl U, Schmiedel D (2022) Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy. Front Immunol 13:822298","journal-title":"Front Immunol"},{"key":"4876_CR162","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","volume":"17","author":"R Elahi","year":"2021","unstructured":"Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A (2021) Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Reviews Rep 17:2081\u20132106","journal-title":"Stem Cell Reviews Rep"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04876-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:55:58Z","timestamp":1736787358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04876-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":162,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["4876"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04876-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors give their consent to submission of this article to Journal of Neuro-oncology (JNO).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}